thalidomide has been researched along with Shingles in 4 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The incidence of herpes zoster is substantial during bortezomib treatment in patients with multiple myeloma (MM)." | 7.81 | Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. ( Choe, PG; Kim, BS; Kim, I; Kim, JW; Koh, Y; Kwon, JH; Min, CK; Mun, YC; Nam, SH; Park, WB; Park, Y, 2015) |
| " We present a case of coinfection with disseminated HSV and VZV infection in a patient taking thalidomide for relapsed multiple myeloma." | 7.71 | Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. ( Curley, MJ; Hassoun, PM; Hussein, SA, 2002) |
| "The incidence of herpes zoster is substantial during bortezomib treatment in patients with multiple myeloma (MM)." | 3.81 | Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy. ( Choe, PG; Kim, BS; Kim, I; Kim, JW; Koh, Y; Kwon, JH; Min, CK; Mun, YC; Nam, SH; Park, WB; Park, Y, 2015) |
| " We present a case of coinfection with disseminated HSV and VZV infection in a patient taking thalidomide for relapsed multiple myeloma." | 3.71 | Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. ( Curley, MJ; Hassoun, PM; Hussein, SA, 2002) |
| " Thalidomide (Synovir), developed by Celgene, has received limited approval for the treatment of leprosy." | 3.70 | FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration. ( Highleyman, L, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| König, C | 1 |
| Kleber, M | 1 |
| Reinhardt, H | 1 |
| Knop, S | 1 |
| Wäsch, R | 1 |
| Engelhardt, M | 1 |
| Kim, JW | 1 |
| Min, CK | 1 |
| Mun, YC | 1 |
| Park, Y | 1 |
| Kim, BS | 1 |
| Nam, SH | 1 |
| Koh, Y | 1 |
| Kwon, JH | 1 |
| Choe, PG | 1 |
| Park, WB | 1 |
| Kim, I | 1 |
| Highleyman, L | 1 |
| Curley, MJ | 1 |
| Hussein, SA | 1 |
| Hassoun, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Immune Response Induced by Zoster Vaccine According to the Timing of Vaccination After Zoster Illness[NCT02704572] | 60 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Comparison of Change in Humoral and Cellular Immunity Induced by Zoster Vaccine According to the Timing of Vaccination After Hematopoietic Stem Cell Transplantation[NCT03192319] | 86 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for thalidomide and Shingles
| Article | Year |
|---|---|
Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
Topics: Acyclovir; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotic Prophylaxis; Antiviral Agent | 2014 |
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Herpes Zoster; Herpesviru | 2015 |
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Herpes Zoster; Herpesviru | 2015 |
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Herpes Zoster; Herpesviru | 2015 |
Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Herpes Zoster; Herpesviru | 2015 |
FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration.
Topics: 2-Aminopurine; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; D | 1998 |
Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma.
Topics: Angiogenesis Inhibitors; Female; Herpes Simplex; Herpes Zoster; Humans; Middle Aged; Multiple Myelom | 2002 |